Future Developments to Minimize ART Risks

Alicia Marzal; Hananel Holzer; Togas Tulandi

doi:10.1055/s-0032-1307423

Seminars in Reproductive Medicine, Inhaltsverzeichnis

Semin Reprod Med 2012; 30(02): 152-160
DOI: 10.1055/s-0032-1307423

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Future Developments to Minimize ART Risks

Alicia Marzal

¹Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada

²Department of Gynecology and Obstetrics, Hospital Universitario La Fe, Valencia, Spain

,

Hananel Holzer

¹Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada

,

Togas Tulandi

¹Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada

› Institutsangaben

Abstract

The most important complications of assisted reproductive techniques are the risk of ovarian hyperstimulation syndrome (OHSS) and the high incidence of multiple pregnancies. Two new strategies are effective in preventing OHSS: the use of anti-müllerian hormone as a marker and the use of dopamine agonists. Genetic markers and vascular endothelial growth factor levels do not predict OHSS. In vitro oocyte maturation treatment should be considered in high responders and in women at risk of OHSS. For prevention of multiple pregnancies, the most effective method is transfer of a single embryo. Preimplantation genetic screening with comparative genomic hybridization, genetic expression of cumulus cells, time-lapse imaging, and respiration rate are emerging technologies for embryo selection that require further study.

Keywords

ART - IVF - OHSS - risk - complication - prevention - risk factor - multiple pregnancies

Volltext

Referenzen

References
1 Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002; 8 (6) 559-577
2 Gerris J. Single-embryo transfer versus multiple-embryo transfer. Reprod Biomed Online 2009; 18 (Suppl. 02) 63-70
3 Ombelet W, De Sutter P, Van der Elst J, Martens G. Multiple gestation and infertility treatment: registration, reflection and reaction—the Belgian project. Hum Reprod Update 2005; 11 (1) 3-14
4 Delvigne A. Symposium: Update on prediction and management of OHSS. Epidemiology of OHSS. Reprod Biomed Online 2009; 19 (1) 8-13
5 Binder H, Dittrich R, Hager I , et al. Association of FSH receptor and CYP19A1 gene variations with sterility and ovarian hyperstimulation syndrome. Reproduction 2008; 135 (1) 107-116
6 Kaiser UB. The pathogenesis of the ovarian hyperstimulation syndrome. N Engl J Med 2003; 349 (8) 729-732
7 Rizk B. Symposium: Update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome. Reprod Biomed Online 2009; 19 (1) 14-27
8 Lussiana C, Guani B, Mari C, Restagno G, Massobrio M, Revelli A. Mutations and polymorphisms of the FSH receptor (FSHR) gene: clinical implications in female fecundity and molecular biology of FSHR protein and gene. Obstet Gynecol Surv 2008; 63 (12) 785-795
9 Smits G, Olatunbosun O, Delbaere A, Pierson R, Vassart G, Costagliola S. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N Engl J Med 2003; 349 (8) 760-766
10 Vasseur C, Rodien P, Beau I , et al. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N Engl J Med 2003; 349 (8) 753-759
11 Montanelli L, Delbaere A, Di Carlo C , et al. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2004; 89 (3) 1255-1258
12 De Leener A, Montanelli L, Van Durme J , et al. Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. J Clin Endocrinol Metab 2006; 91 (2) 555-562
13 Daelemans C, Smits G, de Maertelaer V , et al. Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J Clin Endocrinol Metab 2004; 89 (12) 6310-6315
14 d'Alva CB, Serafini P, Motta E, Kohek MB, Latronico AC, Mendonca BB. Absence of follicle-stimulating hormone receptor activating mutations in women with iatrogenic ovarian hyperstimulation syndrome. Fertil Steril 2005; 83 (6) 1695-1699
15 Kerkelä E, Skottman H, Friden B, Bjuresten K, Kere J, Hovatta O. Exclusion of coding-region mutations in luteinizing hormone and follicle-stimulating hormone receptor genes as the cause of ovarian hyperstimulation syndrome. Fertil Steril 2007; 87 (3) 603-606
16 Weenen C, Laven JS, Von Bergh AR , et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004; 10 (2) 77-83
17 Fanchin R, Schonäuer LM, Righini C, Frydman N, Frydman R, Taieb J. Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod 2003; 18 (2) 328-332
18 Eldar-Geva T, Ben-Chetrit A, Spitz IM , et al. Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod 2005; 20 (11) 3178-3183
19 La Marca A, Giulini S, Tirelli A , et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 2007; 22 (3) 766-771
20 La Marca A, Sighinolfi G, Radi D , et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16 (2) 113-130
21 Lee TH, Liu CH, Huang CC , et al. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008; 23 (1) 160-167
22 Nardo LG, Gelbaya TA, Wilkinson H , et al. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril 2009; 92 (5) 1586-1593
23 Nelson SM, Yates RW, Fleming R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. Hum Reprod 2007; 22 (9) 2414-2421
24 Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update 2011; 17 (1) 46-54
25 La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 2006; 21 (12) 3103-3107
26 Bersinger NA, Wunder D, Birkhäuser MH, Guibourdenche J. Measurement of anti-mullerian hormone by Beckman Coulter ELISA and DSL ELISA in assisted reproduction: differences between serum and follicular fluid. Clin Chim Acta 2007; 384 (1–2) 174-175
27 Aboulghar M. Symposium: Update on prediction and management of OHSS. Prevention of OHSS. Reprod Biomed Online 2009; 19 (1) 33-42
28 Buckett W, Chian RC, Tan SL. Can we eliminate severe ovarian hyperstimulation syndrome? Not completely. Hum Reprod 2005; 20 (8) 2367 ; author reply 2367–2368
29 Verberg MF, Macklon NS, Nargund G , et al. Mild ovarian stimulation for IVF. Hum Reprod Update 2009; 15 (1) 13-29
30 Reinblatt SL, Buckett W. In vitro maturation for patients with polycystic ovary syndrome. Semin Reprod Med 2008; 26 (1) 121-126
31 Le Du A, Kadoch IJ, Bourcigaux N , et al. In vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome: the French experience. Hum Reprod 2005; 20 (2) 420-424
32 Ata B, Togas T. Pathophysiology of ovarian hyperstimulation syndrome and strategies for its prevention and treatment. Expert Rev Obstet Gynecol 2009; 4: 299-311
33 Lim JH, Yang SH, Chian RC. New alternative to infertility treatment for women without ovarian stimulation. Reprod Biomed Online 2007; 14 (5) 547-549
34 Lim JH, Yang SH, Xu Y, Yoon SH, Chian RC. Selection of patients for natural cycle in vitro fertilization combined with in vitro maturation of immature oocytes. Fertil Steril 2009; 91 (4) 1050-1055
35 Huang JY, Chian RC, Tan SL. Ovarian hyperstimulation syndrome prevention strategies: in vitro maturation. Semin Reprod Med 2010; 28 (6) 519-531
36 Buckett WM, Chian RC, Holzer H, Dean N, Usher R, Tan SL. Obstetric outcomes and congenital abnormalities after in vitro maturation, in vitro fertilization, and intracytoplasmic sperm injection. Obstet Gynecol 2007; 110 (4) 885-891
37 Söderström-Anttila V, Salokorpi T, Pihlaja M, Serenius-Sirve S, Suikkari AM. Obstetric and perinatal outcome and preliminary results of development of children born after in vitro maturation of oocytes. Hum Reprod 2006; 21 (6) 1508-1513
38 Cha KY, Chung HM, Lee DR , et al. Obstetric outcome of patients with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer. Fertil Steril 2005; 83 (5) 1461-1465
39 Child TJ, Phillips SJ, Abdul-Jalil AK, Gulekli B, Tan SL. A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries. Obstet Gynecol 2002; 100 (4) 665-670
40 Lim KS, Yoon SH, Lim JH . IVM as an alternative for overresponders; In: Tan SL, Chian RC, Buckett WM, eds. In: In-Vitro Maturation of Human Oocytes: Basic Science to Clinical Application. London, UK: Informa Healthcare; 2007: 345-352
41 Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohí J, Simón C. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril 1999; 71 (3) 482-489
42 Gómez R, Simón C, Remohí J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 2002; 143 (11) 4339-4348
43 Pau E, Alonso-Muriel I, Gómez R , et al. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum Reprod 2006; 21 (6) 1453-1460
44 Ludwig M, Jelkmann W, Bauer O, Diedrich K. Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration. Hum Reprod 1999; 14 (10) 2437-2441
45 Nowicka MA, Fritz-Rdzanek A, Grzybowski W, Walecka I, Niemiec KT, Jakimiuk AJ. C-reactive protein as the indicator of severity in ovarian hyperstimulation syndrome. Gynecol Endocrinol 2010; 26 (6) 399-403
46 Chen CD, Chen HF, Lu HF, Chen SU, Ho HN, Yang YS. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 2000; 15 (5) 1037-1042
47 Artini PG, Fasciani A, Monti M, Luisi S, D'Ambrogio G, Genazzani AR. Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. Fertil Steril 1998; 70 (3) 560-564
48 Agrawal R, Tan SL, Wild S , et al. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril 1999; 71 (2) 287-293
49 Gomez R, Gonzalez-Izquierdo M, Zimmermann RC , et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006; 147 (11) 5400-5411
50 Garcia-Velasco JA. How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists. Reprod Biomed Online 2009; 18 (Suppl. 02) 71-75
51 Alvarez C, Martí-Bonmatí L, Novella-Maestre E , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007; 92 (8) 2931-2937
52 Carizza C, Abdelmassih V, Abdelmassih S , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008; 17 (6) 751-755
53 Youssef MA, van Wely M, Hassan MA , et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update 2010; 16 (5) 459-466
54 Colao A, Galderisi M, Di Sarno A , et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008; 93 (10) 3777-3784
55 Busso C, Fernández-Sánchez M, García-Velasco JA , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod 2010; 25 (4) 995-1004
56 Kol S, Itskovitz-Eldor J. Severe OHSS: yes, there is a strategy to prevent it!. Hum Reprod 2000; 15 (11) 2266-2267
57 Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006; 12 (2) 159-168
58 Humaidan P, Bredkjaer HE, Bungum L , et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005; 20 (5) 1213-1220
59 Humaidan P, Papanikolaou EG, Tarlatzis BC. GnRHa to trigger final oocyte maturation: a time to reconsider. Hum Reprod 2009; 24 (10) 2389-2394
60 Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010; 93 (3) 847-854
61 Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Kolibianakis EM. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online 2007; 15 (4) 408-412
62 Lainas TG, Sfontouris IA, Zorzovilis IZ , et al. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online 2009; 18 (1) 15-20
63 Giles J, Requena A, García-Velasco JA, Pacheco A, Pellicer J, Pellicer A. GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study. Fertil Steril 2009; 91 (4, Suppl) 1366-1369
64 Ferraretti AP, Gianaroli L, Magli C, Fortini D, Selman HA, Feliciani E. Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. Hum Reprod 1999; 14 (6) 1457-1460
65 Aflatoonian A, Oskouian H, Ahmadi S, Oskouian L. Can fresh embryo transfers be replaced by cryopreserved-thawed embryo transfers in assisted reproductive cycles? A randomized controlled trial. J Assist Reprod Genet 2010; 27 (7) 357-363
66 D'Angelo A, Amso N. Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2007; (3) CD002806
67 Walker MC, Murphy KE, Pan S, Yang Q, Wen SW. Adverse maternal outcomes in multifetal pregnancies. BJOG 2004; 111 (11) 1294-1296
68 Lukassen HG, Braat DD, Wetzels AM , et al. Two cycles with single embryo transfer versus one cycle with double embryo transfer: a randomized controlled trial. Hum Reprod 2005; 20 (3) 702-708
69 Thurin A, Hausken J, Hillensjö T , et al. Elective single-embryo transfer versus double-embryo transfer in in vitro fertilization. N Engl J Med 2004; 351 (23) 2392-2402
70 Mastenbroek S, van der Veen F, Aflatoonian A, Shapiro B, Bossuyt P, Repping S. Embryo selection in IVF. Hum Reprod 2011; 26 (5) 964-966
71 Zhang X, Jafari N, Barnes RB, Confino E, Milad M, Kazer RR. Studies of gene expression in human cumulus cells indicate pentraxin 3 as a possible marker for oocyte quality. Fertil Steril 2005; 83 (Suppl. 01) 1169-1179
72 McKenzie LJ, Pangas SA, Carson SA , et al. Human cumulus granulosa cell gene expression: a predictor of fertilization and embryo selection in women undergoing IVF. Hum Reprod 2004; 19 (12) 2869-2874
73 Assou S, Haouzi D, Mahmoud K , et al. A non-invasive test for assessing embryo potential by gene expression profiles of human cumulus cells: a proof of concept study. Mol Hum Reprod 2008; 14 (12) 711-719
74 Hamel M, Dufort I, Robert C , et al. Identification of differentially expressed markers in human follicular cells associated with competent oocytes. Hum Reprod 2008; 23 (5) 1118-1127
75 Harper J, Coonen E, De Rycke M , et al. What next for preimplantation genetic screening (PGS)? A position statement from the ESHRE PGD Consortium Steering Committee. Hum Reprod 2010; 25 (4) 821-823
76 Mastenbroek S, Scriven P, Twisk M, Viville S, Van der Veen F, Repping S. What next for preimplantation genetic screening? More randomized controlled trials needed?. Hum Reprod 2008; 23 (12) 2626-2628
77 Hellani A, Abu-Amero K, Azouri J, El-Akoum S. Successful pregnancies after application of array-comparative genomic hybridization in PGS-aneuploidy screening. Reprod Biomed Online 2008; 17 (6) 841-847
78 Fragouli E, Alfarawati S, Daphnis DD , et al. Cytogenetic analysis of human blastocysts with the use of FISH, CGH and aCGH: scientific data and technical evaluation. Hum Reprod 2011; 26 (2) 480-490
79 Wong CC, Loewke KE, Bossert NL , et al. Non-invasive imaging of human embryos before embryonic genome activation predicts development to the blastocyst stage. Nat Biotechnol 2010; 28 (10) 1115-1121
80 Meseguer M, Hilligsøe KM, Pedersen KS , et al. Pregnancy rates after incubation in new time-lapse incubator (embryoscope) providing detailed information about embryo development compared to incubation in a standard incubator. Paper presented at: ASRM Annual Meeting; October 2010; Denver, CO
81 Cruz M, Gadea B, Garrido N , et al. Embryo quality, blastocyst and ongoing pregnancy rates in oocyte donation patients whose embryos were monitored by time-lapse imaging. J Assist Reprod Genet 2011; 28 (7) 569-573
82 Herrero J, Alberto T, Ramsing NB , et al. Linking successful implantation with the exact timing of cell division events obtained by time-lapse system in the embryoscope. Paper presented at: ASRM Annual Meeting; October 2010; Denver, CO
83 Leese HJ. What does an embryo need?. Hum Fertil (Camb) 2003; 6 (4) 180-185
84 Lopes AS, Larsen LH, Ramsing N , et al. Respiration rates of individual bovine in vitro-produced embryos measured with a novel, non-invasive and highly sensitive microsensor system. Reproduction 2005; 130 (5) 669-679
85 Lopes AS, Madsen SE, Ramsing NB, Løvendahl P, Greve T, Callesen H. Investigation of respiration of individual bovine embryos produced in vivo and in vitro and correlation with viability following transfer. Hum Reprod 2007; 22 (2) 558-566
86 Lopes AS, Lane M, Thompson JG. Oxygen consumption and ROS production are increased at the time of fertilization and cell cleavage in bovine zygotes. Hum Reprod 2010; 25 (11) 2762-2773
87 Tejera A, Herrero J, Ramsing NB , et al. Embryo respiration measurements used for quantification of embryo quality; embryo respiration correlates with ongoing pregnancy and implantation in oocyte donation program. Paper presented at: 26th Annual Meeting of the European Society of Human Reproduction and Embryology; June 27–30, 2010; Rome, Italy
88 Morón FJ, de Castro F, Royo JL , et al. Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS). Pharmacogenet Genomics 2006; 16 (7) 485-495
89 Gao MZ, Zhao XM, Sun ZG, Hong Y, Zhao LW, Zhang HQ. Endocrine gland-derived vascular endothelial growth factor concentrations in follicular fluid and serum may predict ovarian hyperstimulation syndrome in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2011; 95 (2) 673-678
90 Lin YH, Hwang JL, Huang LW , et al. Combination of FSH priming and hCG priming for in-vitro maturation of human oocytes. Hum Reprod 2003; 18 (8) 1632-1636
91 Reinblatt SHH, Son WY, Shalom-Paz E , et al. Optimizing outcomes of IVM treatment cycles-results of a new and improved protocol. Paper presented at: 26th Annual Meeting of the European Society of Human Reproduction and Embryology; June 27–30, 2010; Rome, Italy
92 Fadini R, Dal Canto MB, Mignini Renzini M , et al. Effect of different gonadotrophin priming on IVM of oocytes from women with normal ovaries: a prospective randomized study. Reprod Biomed Online 2009; 19 (3) 343-351
93 Assou S, Haouzi D, De Vos J, Hamamah S. Human cumulus cells as biomarkers for embryo and pregnancy outcomes. Mol Hum Reprod 2010; 16 (8) 531-538